Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;29(1):35-49.
doi: 10.1016/j.soc.2019.08.003. Epub 2019 Oct 29.

Genomics and the History of Precision Oncology

Deborah B Doroshow  1 , James H Doroshow  2
Affiliations
Review

Genomics and the History of Precision Oncology

Deborah B Doroshow et al. Surg Oncol Clin N Am. 2020 Jan.

Abstract

Progress toward the implementation of a molecular characterization paradigm in cancer drug development over the past 20 years has markedly enhanced our capability to select patients who are more likely to benefit from cancer therapy. Improvements in genomic and related diagnostic testing platforms have permitted evaluation of the efficacy of treatment assignment based on predefined biologic features of a patient's tumor or germline using master protocols that may include many malignancies and their molecularly characterized subsets. With this approach, a wide range of new targeted and immunologic treatment approaches have been defined for patients who, heretofore, lacked effective therapeutic options.

Keywords: Basket trial; Bucket trial; Cancer drug development; Master protocol; Precision oncology.

PubMed Disclaimer

References

    1. Doroshow JH. Precision medicine in oncology In: DeVita VT, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 11th ed. Philadelphia: Wolters Kluwer; 2019:186–196.
    1. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer. N Engl J Med. 2018;379:111–121. - PMC - PubMed
    1. Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18:1590–1599. - PMC - PubMed
    1. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–1765. - PubMed
    1. Khorashad JS, Kelley TW, Szankasi P, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013;121:489–498. - PMC - PubMed

MeSH terms